Loading
Two years of an olaparib pill after chemotherapy made a large share of women with BRCA-mutated ovarian cancer long-term survivors.
PFS HR 0.30 at the primary analysis (NEJM 2018). At 7 years, 67.0% of olaparib patients were alive versus 46.5% on placebo (HR 0.55; JCO 2023), the first PARP inhibitor trial with a clinically meaningful overall survival gain in the first-line setting and the basis for the 2018 maintenance approval. Roughly half of olaparib patients remained progression-free at 5 years.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
391 randomised.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Olaparib | 260 | - | 0.3 (0.23 to 0.41) | - | link |
| Placebo | 131 | - | ||||
| Overall survival at 7 years | Olaparib | - | 67% | 0.55 (0.4 to 0.76) | - | link |
| Placebo | - | 46.5% |
Shares ctDNA-guided duration of PARP maintenance, Kathleen N. Moore, High-grade serous ovarian cancer, Platinum-sensitive ovarian cancer.
Shares High-grade serous ovarian cancer, PARP inhibitors, Olaparib, AstraZeneca.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Olaparib, AstraZeneca.
Shares ctDNA-guided duration of PARP maintenance, High-grade serous ovarian cancer, Platinum-sensitive ovarian cancer, PARP.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
Shares High-grade serous ovarian cancer, Platinum-sensitive ovarian cancer, PARP, PARP inhibitors.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.